display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
mBC - TNBC - L1 - all populationmBC - TNBC - L1 - PDL1 positive
pembrolizumab plus SoC KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-355 ...

Study type: